ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GPCR Structure Therapeutics Inc

36.07
0.00 (0.00%)
Pre Market
Last Updated: 13:03:45
Delayed by 15 minutes
Name Symbol Market Type
Structure Therapeutics Inc NASDAQ:GPCR NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 36.07 32.10 39.11 0 13:03:45

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

08/03/2024 9:05pm

GlobeNewswire Inc.


Structure Therapeutics (NASDAQ:GPCR)
Historical Stock Chart


From Feb 2024 to May 2024

Click Here for more Structure Therapeutics Charts.

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that Raymond Stevens, Ph.D., the Company’s Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 AM ET in Miami, Florida.

The live and archived webcast of the presentation will be accessible from the company’s website https://ir.structuretx.com/events-presentations/events. The replay of the webcast will be available for 90 days.

About Structure TherapeuticsStructure Therapeutics is a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative oral treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a scientifically-driven, GPCR-targeted pipeline, featuring two wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.

Contacts:

Investors:Danielle KeatleyStructure Therapeutics Inc.ir@structuretx.com

Media:Dan Budwick1ABDan@1abmedia.com

1 Year Structure Therapeutics Chart

1 Year Structure Therapeutics Chart

1 Month Structure Therapeutics Chart

1 Month Structure Therapeutics Chart

Your Recent History

Delayed Upgrade Clock